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Abstract
Although extensive evidence supports the role of amyloid-β (Aβ) in Alzheimer disease (AD), the
neurotoxic mechanisms underlying AD pathogenesis are not understood. On the other hand,
neuronal loss is the pathological feature that best correlates with cognitive impairment. We
hypothesized that cholinergic neurodegeneration may lead to Aβ deposition and tested this by
inducing selective cholinergic lesions in APPswe/PS1dE9 mice with murine p75NTR saporin (mu
p75-SAP). Intracerebroventricular lesions that removed ~50% of cholinergic innervation to the
cortex and hippocampus were induced in animals with incipient (~3 months) and marked (~7
months of age) Aβ deposition. Cranial windows were implanted and Aβ deposition was monitored
in vivo using multiphoton microscopy. Aβ deposition was increased as soon as 7 days after the
lesion and this effect was maintained up to 3 months later. Postmortem studies using
immunohistochemistry with an anti-Aβ antibody corroborated these findings in both cerebral
cortex and hippocampus. Tau phosphorylation was also significantly increased after the lesions.
Cholinergic denervation resulted in early memory impairment at 3 months of age that worsened
with age (~7 months); there was a synergistic effect between cholinergic denervation and the
presence of APP/PS1 transgenes. Altogether, our data suggest that cholinergic denervation may
trigger Aβ deposition and synergistically contribute to cognitive impairment in AD patients.
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INTRODUCTION
Alzheimer disease (AD) is the most common cause of dementia among elderly people.
Although the ultimate neurotoxic mechanisms have not been completely elucidated, major
hallmarks of the disease include senile plaques (SPs), mainly composed of amyloid-β (Aβ),
neurofibrillary tangles, consisting of aggregated hyperphosphorylated tau protein, and
neuronal loss (1, 2). Specifically, cholinergic cell loss in the basal forebrain (BFB), the
major source of cortical and hippocampal cholinergic projections, seems to correlate better
than SPs and tangles with clinical dementia in AD (3). A close relationship has also been
documented between Aβ deposition and neurodegeneration, and previous studies have
shown that senile plaque (SP) deposition can lead to neuronal abnormalities (4, 5).
Cholinergic neurons seem to be particularly highly susceptible in AD (6), and experimental
cholinergic denervation may interfere with amyloid precursor protein (APP) (6). Moreover,
cholinergic loss might exacerbate cognitive impairment in experimental AD (7). However,
to our knowledge, whether specific cholinergic neurodegeneration leads to SP deposition in
innervated areas remains unclear.
Different transgenic mice, including APPswe/PS1dE9 mice, have been developed to study
the etiology, evolution and new therapeutic alternatives of AD. These mice are widely used
by the scientific community because they show SP deposition at 4 to 6 months of age (8, 9)
as well as learning and memory deficits by 8 months (10). As in other AD transgenic
models, however, they do not reproduce the complexity of the illness because they do not
show overt neuronal loss or tau pathology (11). Although previous studies have found
evidence of cholinergic terminal abnormalities in this and other transgenic AD mouse
models, BFB cholinergic somata seem to be preserved (11, 12). Therefore, producing an
animal model that shows both specific neuronal loss and Aβ deposition could help elucidate
the relationship between SPs and cholinergic denervation observed in human AD. In order
to develop such a model, we selectively removed BFB cholinergic neurons in APPswe/
PS1dE9 mice using murine p75NTR saporin (mu p75-SAP), a highly specific cholinergic
immunotoxin that selectively targets the mouse p75NTR receptor (7). By injecting the
immunotoxin into the lateral ventricles, we were able to reach the BFB, including the
nucleus basalis of Meynert and medial septum, major sources of cortical and hippocampal
cholinergic innervation. We used in vivo multiphoton microscopy (MPM) to assess acute
and long-term SP deposition in young and adult APPswe/PS1dE9 mice upon BFB
cholinergic denervation and assessed learning and memory deficits in the mice.
MATERIALS AND METHODS
Animals and Cholinergic Denervation
APPswe/PS1dE9 mice were obtained from Jackson Laboratory (Bar Harbor, ME). Animals
were aged to ~3 and ~7 months of age and experimental procedures were approved by the
Massachusetts General Hospital and the Animal Care and Use Committee of the University
of Cadiz, in accordance with the Guidelines for Care and Use of experimental animals
(European Commission Directive 86/609/CEE and Spanish Royal Decree 1201/2005).
To remove cholinergic innervation to the cortex and hippocampus, the BFB was exposed to
the cholinergic specific immunotoxin mu p75-SAP (Advanced Targeting Systems, San
Diego, CA), as previously described (11, 13, 14). Vehicle-injected animals were used as
controls (Sham). Acute lesions were performed in ~3-month-old (Wild type (Wt) Sham n =
16, Wt Sap n = 13, APP/PS1 Sham n = 17, APP/PS1 Sap n = 12) and ~7-month-old mice
(Wt Sham n = 19, Wt Sap n = 15, APP/PS1 Sham n = 17, APP/PS1 Sap n = 19). To
determine whether lesions were completely established 1 week after the injection (when
animals were tested for in vivo Aβ deposition and learning and memory abilities), a group of
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7-month-old mice (n = 3) was lesioned and killed 7 days later to determine the extent of the
lesion at that time. A group of lesioned ~3-month-old mice (Wt Sham n = 18, Wt Sap n =
13, APP/PS1 Sham n = 17, APP/PS1 Sap n = 19) was allowed to age to asses long-term
lesion effects. Long-term lesioned mice were tested for Aβ deposition and behavioral
impairment immediately before sacrifice at 7 months of age. Behavioral tests were
performed on all animals that did not undergo in vivo imaging. For postmortem studies, half
of the brains were fixed in paraformaldehyde (PFA) for immunohistochemistry studies and
the rest were fresh frozen for biochemical determinations.
Briefly, mice were anesthetized with a subepidermal injection of xylazine (10 mg/kg)
(Rompun 2%, Bayer Pharma, San Juan Despi, Spain) and an i.p. injection of ketamine (100
mg/kg) (Imalgene 500, Merial, Tarragona, Spain) and placed in a stereotaxic device. Lesions
of the BFB were performed by bilateral intracerebroventricular injections (AP −0.6 mm; ML
±1.2 mm; DV +2 mm from bregma) of the immunotoxin mu p75-SAP (1–1.2 µg/µl), diluted
in phosphate buffered saline. We injected 1 µl/hemisphere using a Hamilton syringe at a
constant flow rate of 0.1 µl/minute for 10 minutes; a delay of 10 minutes was allowed before
complete retraction of the needle to minimize aspiration of the toxin. Sham operated mice
followed the same procedure but only phosphate buffered saline was injected.
Actimetry and New Object Discrimination Tests
Episodic memory in young and older mice treated with mu p75-SAP was assessed with the
New Object Discrimination (NOD) test as previously described with minor modifications
(15). Acutely lesioned mice, ~3 months old (APP/PS1 Sap n = 10, APP/PS1 Sham n = 9, Wt
Sap n = 9, Wt Sham n = 9) and ~7 months old (APP/PS1 Sap n = 8, APP/PS1 Sham n = 8,
Wt Sap n = 9, Wt Sham n = 14) mice were tested 7 days after the lesions, when cholinergic
denervation was established (16–18). Long-term mu p75-SAP-treated mice were evaluated
at the age of 7 months (APP/PS1 Sap n = 7, APP/PS1 Sham n = 9, Wt Sap n = 6, Wt Sham n
= 17), before death. We assessed locomotor activity of all the animals in the study by
measuring the distance travelled by mice for 30 minutes prior to the commencement of the
NOD test. Testing was conduced for 3 consecutive days as follows: On day 1, mice were
habituated for 30 minutes to a transparent rectangular box (22 cm long × 44 cm width × 40
cm high), where the procedure takes place. On day 2, animals were exposed to 2 objects for
habituation purposes that were not used again during the object exploration task. On day 3,
each mouse received 2 sample trials and a test trial. On the first sample trial, mice were
placed in the center of the box containing 3 copies of a novel object arranged in a triangle-
shaped spatial configuration and allowed to explore them for 5 minutes. After a delay of 30
minutes, mice received a second sample trial with 4 novel objects, arranged in a quadratic-
shaped spatial configuration for 5 minutes. After a delay of 30 minutes, mice received a test
trial with 2 copies of the object from sample trial 2 placed at the same position (“recent non-
displaced” objects) and 2 copies of the object from sample trial 1 (“old” objects) placed one
of them at the same position (“old non-displaced” object) and the other in a new position
(“old displaced” object). Integrated memory for "what," "where," and "when" were analyzed
as previously described (15): "What" was defined as the difference in time exploring
familiar and recent objects; "where" was defined as the difference in time exploring
displaced and non-displaced objects; and "when" was defined as the difference between time
exploring "old non-displaced" and "recent non-displaced" objects (15).
Morris Water Maze
Learning and memory abilities were further analyzed in animals that underwent the NOD
test, using the Morris Water Maze test as previously described with minor modifications
(19). All groups under study, i.e. those with 3-month-old acute lesions (APP/PS1 Sap n = 11
APP/PS1 Sham n = 10, Wt Sap n = 8, Wt Sham n = 9), 7-month-old acute lesions (APP/PS1
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Sap n = 9, APP/PS1 Sham n = 11, Wt Sap n = 11, Wt Sham n = 18), and 7-month-old long-
term lesions (APP/PS1 Sap n = 7, APP/PS1 Sham n = 8, Wt Sap n = 6, Wt Sham n = 17)
were tested. Experiments commenced the day after the conclusion of the NOD test for all
the groups. The maze consisted of a round tank of water (0.95 m in diameter) with 4 equal
virtual quadrants indicated with geometric cues mounted on the walls. An escape platform
was 2 to 3 cm below the water surface and was camouflaged with calcium carbonate to
cloud the water. Water temperature was 21 ± 1°C. A camera was mounted above the maze
and attached to a computer with the software Smart (Panlab, Barcelona, Spain). Testing was
conducted in 2 phases: acquisition and retention. Acquisition consisted of 4 trials/day for 4
days with the platform submerged. During this phase the platform was located in quadrant 2.
The time limit was 60 seconds/trial with an intertrial interval of 10 minutes. If the animal did
not find the platform it was placed on it for 10 seconds. The retention phase began a day
after acquisition testing. It consisted of a single trial with the platform removed. Average
times to locate the platform during the acquisition phase, as well as the percentage of total
time spent in each quadrant during the retention phase, were determined.
In Vivo Assessment of SP Deposition Using MPM
To perform in vivo imaging, cranial windows were placed immediately after surgery, as
previously described with minor modifications (20). Briefly, a 6-mm craniotomy was drilled
between Bregma and Lambda sutures and a glass coverslip was attached with dental cement.
Fluorescent angiograms were included to facilitate finding the same cerebral regions
between sessions using fluorescent injections in the lateral tail vein with Texas Red Dextran
70 KD (Invitrogen, Carlsbad, CA). Methoxy-XO4 (5 mg/kg), a Congo red derivative that
crosses the blood brain barrier and binds fibrillar Aβ (21), was injected i.p. the day before
the imaging session to visualize SPs. Young mice (3 months old, APP/PS1 Sap n = 5, APP/
PS1 Sham n = 5) and older mice (7 months old, APP/PS1 Sap n=4, APP/PS1 Sham n = 4)
were imaged immediately after surgery (day 0), allowed to recover and imaged again on day
7 and day 14. Long-term denervation experiments were also carried out in mice with lesions
performed at 3 months and imaged up to 3.5 months later (at ~7 months) (APP/PS1 Sap n =
4, APP/PS1 Sham n = 4). The images were obtained with a multiphoton microscope Bio-
Rad1024 (Bio-Rad, Hercules, CA) where two-photon fluorescence was generated with 800-
nm excitation from a Ti:Sapphire laser (Mai Tai; Spectra Physics, Mountain View, CA), as
previously described (8, 22). External detectors collected emitted fluorescent light from
methoxy-XO4 and Texas red. Multiple series were imaged and leptomeningeal cerebral
vessels were used as local markers. In vivo imaging was done using a 20× water immersion
objective (Olympus, NA = 0.95, 615×615 µm; z-step, 5 µm, depth, approximately 200 µm).
Maximum intensity projections of z-series were generated using the Image J software.
Stacks were used to measure plaque size and number (23). Senile plaque size was measured
by thresholding, segmenting, and measuring the blue fluorescence channel.
Acetyl Cholinesterase Determination
Extension and selectivity of the lesions were assessed by acetyl cholinesterase (AChE) assay
as previously described with minor modifications (24). Cortex, hippocampus and striatum
from 3 months acute lesioned mice (APP/PS1 Sap n = 6, APP/PS1 Sham n = 6, Wt Sap n =
4, Wt Sham n = 4) 7 months acute lesioned mice (APP/PS1 Sap n = 9, APP/PS1 Sham n =
13, Wt Sap n = 13, Wt Sham n = 19 and 7 months long-term lesioned mice (APP/PS1 Sap n
= 5, APP/PS1 Sham n = 11, Wt Sap n = 11, Wt Sham n = 19) were homogenized in 30
volumes of 75 mM saline phosphate buffer (pH 7.4). Briefly, 111 µl of acetylthiocholine
iodide (Sigma, St. Louis, MO) 0.3 mM, 28 µl of saline phosphate buffer 100 mM (pH 7.4)
and 7 µl of tissue homogenate were incubated in a 96-well plate for 8 minutes at 37°C. The
reaction was then terminated by adding 28 µl of sodium dodecyl sulphate (Sigma) 0.2% (w/
v) and 28 µl of 5.5’-dithio-(2-bisnitrobenzoico) (Sigma) 0.5% (w/v). Color was measured
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spectrophotometrically at 450 nm (MQX200R2, Biotek instruments, Burlington VT). All
samples were assayed in duplicate. Results were expressed as percentage of those obtained
for Wt Sham animals.
Aβ, Choline Acetyltransferase and Parvalbumin Immunohistochemistry
Both acute and long-term mu p75-SAP-treated mice were assessed postmortem for Aβ
burden in cortex and hippocampus at 3 months (APP/PS1 Sap n = 4, APP/PS1 Sham n = 5)
7 months acute (APP/PS1 Sap n = 4, APP/PS1 Sham n = 4) and 7 months long-term (APP/
PS1 Sap n = 4, APP/PS1 Sham n = 4). Immunohistochemistry for Aβ was performed as
previously described (25) with minor modifications. PFA-fixed 30-µm sections were washed
in TBS and pre-treated with 70% formic acid for 30 minutes at room temperature (RT).
Sections were blocked in 5% normal goat serum with 0.5% Triton-X100 for 1 hour. Sections
were rinsed in TBS and incubated with anti-βA1–16 antibody 1:600 (Millipore, Billerica,
MA) in 1% normal goat serum overnight at 4°C. After washing in TBS, sections were
incubated with anti-mouse Alexa Fluor 594 1:200 (Invitrogen) for 1 hour. Senile plaques
were stained with thioflavin S 0.1% (w/v) for 10 minutes and washed in 80% ethanol and
dH2O. The number of plaques, plaque size and plaque burden (expressed as percentage of
analyzed area) were calculated using Adobe Photoshop and Image J software for each age
group under study.
Because AChE is not an exclusive cholinergic marker and can also be detected in synaptic
clefts and cholinoceptive neurons, we further assessed cholinergic denervation of the BFB
by immunohistochemistry for choline acetyltransferase (ChAT) in these regions (n = 3/
group). Although it is mainly cholinergic, the BFB also contains other neuronal populations.
To assess possible nonspecific damage of γ-aminobutyric acid–releasing (GABAergic)
neurons after mu p75-SAP lesions we included double immunostaining for parvalbumin.
Sections were washed in TBS and incubated in 70% formic acid at 37°C for 30 minutes.
After washing, sections were blocked in 5% bovine serum albumin and 0.1% triton-X for 1
hour at RT. Tissue was incubated with primary antibodies anti-ChAT (1:1000) and anti-
parvalbumin (1:1000) (Millipore) in 2.5% bovine serum albumin and 0.1% triton-X for 72
hours at 4°C. After washing, sections were then incubated in Alexa Fluor 594 anti-rabbit and
Alexa Fluor 488 anti-mouse 1:1000 (Invitrogen) at RT for 1 hour. Sections were mounted,
coverslipped and photographed with a fluorescence microscope (Olympus Bc60, Tokyo,
Japan).
Tau and Phospho-tau Levels
Cortical samples from mu p75-SAP-treated and Sham mice 3 months acute (APP/PS1 Sap n
= 8, APP/PS1 Sham n = 8, Wt Sap n = 8, Wt Sham n = 8), 7 months acute (APP/PS1 Sap n
= 6, APP/PS1 Sham n = 6, Wt Sap n = 6, Wt Sham n = 5), and 7 months long-term (APP/
PS1 Sap n = 8, APP/PS1 Sham n = 8, Wt Sap n = 8, Wt Sham n = 8) were homogenized in
lysis buffer (Cell Signaling, Beverly, MA) and supplemented with a protease and
phosphatase inhibitor cocktail (Sigma). The homogenates were sonicated and centrifuged at
4°C for 5 minutes at 15,000 × g. Supernatants were collected and protein concentration
determined using the Bradford protein assay (BioRad, Munich, Germany). Proteins were
separated on 10% acrylamide-bisacrylamide gels, followed by electrophoretic transfer to
PVDF membranes (Schleicher & Schuell, Keene, NH). Membranes were then immersed in
blocking buffer (Invitrogen) for 1 hour and incubated overnight at 4°C with primary
antibodies for total tau (1:1000) (DAKO, Glostrup, Denmark). Membranes were washed and
then incubated with chemiluminescent immunodetection system for mouse and rabbit
primary antibodies respectively (Invitrogen). Membranes were washed and signal was
detected using Novex AP Chemiluminescent Substrate (Invitrogen) and Kodak Biomax
Light Film (Sigma). After stripping, membranes were incubated with anti-phospho-tau
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antibody (1:1000) (clone AT8, Fisher Scientific, Waltham, MA). Immunoblots were semi-
quantified by measuring the optical density of each protein band on scanned film using the
ImageJ software. Each band was normalized to α-tubulin optical density and phospho tau/
total tau ratio was represented as percentage of Wt Sham mice values.
RESULTS
Intracerebroventricular Infusion of the Immunotoxin mu p75-SAP Results in Cortical and
Hippocampal Cholinergic Depletion
Wt and APP/PS1 mice received bilateral injections of the immunotoxin mu p75-SAP into
the lateral ventricles. This procedure allows the immunotoxin to reach BFB areas, including
the nucleus basalis of Meynert and the medial septum, resulting in specific degeneration of
cholinergic neurons in these areas (7). To confirm that mu p75-SAP infusions resulted in
cholinergic denervation, we measured AChE activity in cortex and hippocampus, the main
projection areas of BFB cholinergic neurons. Because behavioral tests and in vivo MPM
were started 1 week after the lesions, we assessed AChE activity in a separate group of mice
at this time point; we observed a similar profile to that observed at 2 weeks.
At 1 week post-lesion, AChE activity, expressed as percentage of Wt Sham values, was
significantly reduced in cortex of Wt and APP/PS1 lesioned mice (Wt Sham: 100.00 ± 2.20,
Wt SAP: 57.45 ± 6.47, APP/PS1 Sham: 90.80 ± 9.79, APP/PS1 SAP:55.27 ± 7.76,
[F(3,31)=7.097, ** p=0.01 vs. Wt Sham]). A similar profile was observed in the hippocampus
(Wt Sham: 100.00 ± 15.07, Wt SAP: 45.81 ± 3.40, APP/PS1 Sham: 88.20 ± 4.67, APP/PS1
SAP: 57.38 ± 3.48, [F(3,32)=15.309, ** p < 0.01 vs. Wt Sham]). Cholinergic activity in the
striatum was preserved (Wt Sham: 100.00 ± 12.82, Wt SAP: 84.86 ± 10.90, APP/PS1 Sham:
106.74 ± 11.62, APP/PS1 SAP: 84.34 ± 2.60, [F(3,31)=1.612, p=0.206]). When AChE
activity was assessed 2 weeks after the lesion (when behavioral assessment was completed),
both Wt and APP/PS1 denervated mice showed a ~40% to 50% reduction of AChE activity
in cortex and hippocampus, whereas areas not innervated by the BFB (e.g. striatum) were
intact, indicating selectivity of the lesion (Table). We observed a slight, non-significant,
reduction in AChE activity in Sham transgenic mice, compared to Wt Sham, suggesting
some cholinergic degeneration in this animal model, as previously described (11). Further
confirmation of BFB cholinergic loss was obtained using immunohistochemistry for ChAT
in the medial septum. There was a reduction in ChAT staining in mu p75-SAP-infused
animals, whereas parvalbumin-positive neurons were preserved in lesioned mice, supporting
the specificity of the cholinergic denervation (Fig. 1).
Effect of Cholinergic Denervation on Cognition
Prior to cognition studies, motor function integrity was assessed in all animal groups. The
actimetry test revealed that distance travelled and speed were similar in all groups (3 and 7
months of age) (data not shown). This indicated that motor disturbances were absent, that
mu p75-SAP-induced lesions were limited to the denervated areas, and that Purkinje cells
were likely preserved. We performed NOD tests to evaluate episodic memory in Wt and
APP/PS1 mice with or without cholinergic denervation. The NOD task test assesses episodic
memory and is a very sensitive tool to detect early memory alterations in animal models.
There was general impairment in episodic memory in all denervated mice at 3 and 7 months
of age (both those that were acutely and those that were chronically lesioned). All 3
parameters analyzed (“what,” “where,” and “when”) were significantly impaired in mu p75-
SAP-treated mice and there was also an overall worsened performance associated with
aging. In aged mice (7 months old) vs. 3 months old mice a significant age X transgene
effect for all paradigms (what: [F(2,1)=12.243, p < 0.01), where: [F(2,1)=13.81, p=0.023),
when: [F(2,1)=19.710, p < 0.01), supporting an age effect on episodic memory. There was a
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significant effect in young transgenic mice (3 months of age) (Fig. 2), independent of the
presence of a cholinergic lesion, whereas at 7 months of age, the cholinergic lesion
worsened the performance of transgenic lesioned mice. Statistical analysis included one-way
ANOVA followed by Tukey-b or Tamhane tests, as required for each variable. Assessment
of the difference in time exploring familiar and recent objects (what) indicated significant
impairment in 3-month-old transgenic mice without a significant effect of the mu p75-SAP
lesions [F(3,107)=21.208, ** p < 0.01 vs. Wt mice] (Fig. 2). In older mice (7 months of age),
we observed some effect on episodic memory and a significantly worse performance of
transgenic lesioned mice vs. the other groups in relation to parameter "what" [F(3,155)=10.39,
* p < 0.01 vs. other groups] (Fig. 2). A similar profile was observed in long-term lesioned
mice [F(3,68)=22.212, ** p < 0.01 vs. Wt mice]. Episodic memory for "where" was
significantly affected in 3-month-old transgenic mice; transgenic lesioned mice showed a
slightly worse performance [F(3,113)=7.349, ** p < 0.01 vs. Wt mice] (Fig. 2). Older mice (7
months of age) showed a more substantial deficit for the "where" paradigm when transgenic
lesioned mice were compared to the other groups [F(3,125)=3.68, * p = 0.014 vs. Wt Sham
mice]. We also observed a worsening effect of the cholinergic lesion in APP/PS1 mice in
long-term experiments [F(3,66)=6.23, ** p < 0.01 vs. Wt mice]. Episodic memory ("when")
was affected at 3 months of age in transgenic mice [F(3,113)=6.98, ** p < 0.01 vs. Wt mice]
(Fig. 2), but at 7 months of age only lesioned transgenic mice were significantly affected at
this level [F(3,122)=37.056, * p=<0.01 vs. other groups] (Fig. 2). Long-term studies showed a
similar profile, i.e. there was increased impairment in transgenic mice with a cholinergic
lesion [F(3,64)=17.801, * p < 0.01 vs. Wt mice]. All 3 parameters analyzed were significantly
impaired in 7-month-old lesioned transgenic mice, when Aβ deposition is well established.
Altogether the NOD test showed that cholinergic lesions of the BFB significantly impaired
episodic memory, particularly in older mice with higher amyloid burden.
Spatial learning and memory abilities were analyzed in all age groups using the Morris
Water Maze test. We analyzed the time to locate the hidden platform during the acquisition
phase and we used two-way ANOVA (group X day) to detect differences among groups.
Further daily comparisons were performed with one-way ANOVA followed by Tukey-b test
or Tamhane test, as required. We observed early cognitive impairment in 3-month-old
acutely lesioned mice when we analyzed the time to locate the platform [F(9,518)=1.921,
p=0.047] (Fig. 3A). Daily analysis showed an overall delay lo locate the platform for
transgenic lesioned mice (day 1: [F(3,144)=9.79, ** p < 0.01 vs. Wt Sham], day 2:
[F(3,140)=17.910, ** p < 0.01 vs. Wt Sham and Wt p-75 SAP, †† p < 0.01 vs. Wt Sham], day
3: [F(3,133)=17.346, ** p < 0.01 vs. other groups, †† p < 0.01 vs. Wt Sham ], day 4:
[F(3,134)=14.025, ** p < 0.01 vs. other groups]). In 7-month-old mice we observed cognitive
alterations in animals bearing the APP/PS1 transgenes and we observed a worsening effect
on those animals with acute cholinergic denervation (group X day) [F(9,1008)=2.781, p =
0.03] (Fig. 3A). Further daily analysis corroborated these observations and we detected
learning and memory impairment throughout the 4 days of the acquisition phase (day 1:
[F(3,272)=10.611, ** p<0.01 vs. Wt Sham], day 2: [F(3,272)=22.398, ** p < 0.01 vs. Wt
Sham], day 3: [F(3,262)=13.605, ** p < 0.01 vs. Wt Sham and APP/PS1 Sham, †† p < 0.01
vs. Wt Sham], day 4: [F(3,266)=24.109, ** p < 0.01 vs. Wt Sham and APP/PS1 Sham, †† p <
0.01 vs. Wt Sham]). A similar profile was observed in 7-month-old mice with chronic
cholinergic lesions. The presence of the APP/PS1 transgenes was enough to impair learning
and memory abilities in the water maze; however, this effect was worsened in the presence
of the cholinergic lesion (group X day) [F(9,546)=2.108, p = 0.027] (Fig. 3A). Further daily
analysis corroborated these observations (day 1: [F(3,141)=19.203, ** p < 0.01 vs. Wt Sham];
day 2: [F(3,151)=9.385, ** p < 0.01 vs. other groups, †† vs. Wt Sham]; day 3:
[F(3,143)=19.199 ** p < 0.01 vs. other groups, †† p < 0.01 vs. Wt Sham]; day 4:
[F(3,143)=19.199, ** p < 0.01 vs. other groups, †† p < 0.01 vs. Wt Sham]). We observed
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some age-related learning and memory deficits in Wt mice that were not significantly
different than those observed in Wt mu p75-SAP-treated mice.
We further analyzed the synergistic effect between the presence of a cholinergic lesion and
the APP/PS1 transgenes along the fourth day of the acquisition phase, when differences
among groups were most marked. At 3 months of age, we did not detect a significant
transgene X lesion effect (F(3,1)=6.285, p = 0.651); however, in older groups we detected a
significant transgene X lesion effect, both in acute (F(3,1)=4.24, * p=0.04) and long-term
studies (F(3,1)=6.285, * p = 0.013), supporting a synergistic effect between the APP/PS1
transgenes and the lesion with mu p75-SAP.
In the retention phase, which tests memory preservation, we measured the percentage of
time spent by the animals in the quadrant number 2, where the platform was located during
the acquisition phase (Fig. 3B). Using one-way ANOVA we did not detect statistical
differences among 3-month-old groups of mice (mu p75-SAP transgenic vs. other groups)
[F(3,34)=0.635, p = 0.597]. Seven-month-old transgenic mice with acute or chronic
cholinergic lesions showed difficulties in remembering the quadrant where the platform used
to be located (quadrant 2) and they spent significantly shorter times in this area (acute
lesion: [F(3,62)=2.858, * p = 0.04 vs. other groups]; long-term lesion: [F(3,34)=3.134, * p =
0.038 vs. other groups]). We observed that groups that presented some learning impairment
during the acquisition phase also showed some limitations during the retention phase,
although these differences did not reach statistical significance in the case of APP/PS1 Sham
or Wt SAP-treated mice, when compared to Wt Sham mice (Fig. 3B). Altogether, our
observations in the behavioral tests support the worsening effect of the cholinergic lesion in
the pathological condition of APP/PS1 mice, affecting both episodic memory, as shown in
the NOD test, as well as spatial and working memory in the Morris Water Maze test.
Effect of mu p75-SAP-induced Lesions on Aβ Deposition In Vivo and in Real Time
We used longitudinal in vivo MPM imaging to test the effect of mu p75-SAP-induced
lesions on amyloid deposition in transgenic mice. Although we randomly assessed Wt mice,
we did not detect any SPs in lesioned or Sham mice. Senile plaques in the cortex labeled
with methoxy-XO4, were measured in transgenic mice and counted at 3 time points:
immediately after the lesions; 7 days post-lesion; and 14 days post-lesion. Fluorescent
angiograms were used as independent fiduciary markers to locate the same cortical regions
at all 3 time points. We observed a significant increase in the deposition of SPs as soon as 7
days after the lesions when compared to Sham mice, both in young animals (~3 months of
age) (Fig. 4A), with very limited amounts of Aβ, and in mice at ~7 months of age, with
robust SP deposition (Fig. 4B). Although we observed a similar profile in SP deposition
after cholinergic lesions, both in young and older mice, deposition rates were more robust in
aged mice, supporting previous observations (8) and suggesting that cholinergic denervation
triggers and accelerates amyloid deposition. This reinforcing effect of cholinergic
denervation on amyloid deposition is depicted in Figure 4D–K. Sham-treated mice showed a
rate of deposition of ~8 SPs/mm3/week, similar to that described previously (26). Long-term
treated animals were assessed for in vivo deposition of Aβ at 3 months of age as well as one
last time before death at 7 months of age. There was a significant increase in numbers of SPs
deposited in mice with lesions when compared with Sham mice over this ~3.5 month period
(Fig. 4).
We did not observe significant plaque clearance in any of the groups; therefore, the overall
number of plaques increased over time. Vascular amyloid deposition in the APP/PS1 mouse
is modest and we did not observe any gross changes in amyloid angiopathy progression or
clearance due to the lesions.
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Postmortem Assessment of Aβ deposition
Because the hippocampus cannot be chronically imaged in vivo using MPM, we assessed
the effect of cholinergic denervation on hippocampal and cortical SP deposition by
postmortem histochemical studies in APP/PS1 mice. Compared to Sham animals, mu p75-
SAP-treated transgenic mice showed a significant increase in Aβ staining at different stages
of aggregation (Aβ and compact SPs). This result was confirmed with both an anti-Aβ
antibody and thioflavin S (TS) staining, which gave similar staining profiles (Fig. 5). Using
the Student t-test for independent samples there was a significant increase in cortical plaque
burden after denervation in all age groups studied, although this increase was more marked
in 7-month-old mice, particularly in those with long-term lesions (Fig. 5A) (3 months acute:
Aβ, * p = 0.045 vs. Sham; TS, * p = 0.045 vs. Sham, 7 months acute: Aβ, * p = 0.018 vs.
Sham; TS, * p = 0.026 vs. Sham, 7 months long term: Aβ, * p = 0.044 vs. Sham; TS, * p =
0.041 vs. Sham).
We could not detect plaques in the hippocampus in 3-month-old Sham mice; only mu p75-
SAP-injected mice had SPs at that early stage, indicating an acceleration of plaque
deposition with a cholinergic lesion. There was a significant increase in amyloid burden in
hippocampus of cholinergic denervated mice at 7 months of age (7 months acute: Aβ, * p =
0.019 vs. Sham; TS, * p = 0.025 vs. Sham, 7 months long term: Aβ, * p = 0.022 vs. Sham;
TS, * p = 0.046 vs. Sham). Mean SP size was similar in all animals, both in the cortex (Fig.
5A) (3 months acute: Aβ, p = 0.915; TS, p = 9.963, 7 months acute: p = 0.879, 7 months
long term: p = 0.417) and the hippocampus (7 months acute: Aβ, p = 0.879; TS, p = 0.066, 7
months long term: Aβ, p = 0.158; TS, p = 0.950), indicating that SP sizes are stable as the
disease processes evolve.
We detected a significant increase in numbers of deposited plaques in 3-month-old acute
lesioned mice in cortex (Aβ: * p < 0.01 vs. Sham, TS: * p = 0.012 vs. Sham). Similar
profiles were observed in 7-month-old acute lesioned mice in cortex (Fig. 5A) (Aβ: * p =
0.027 vs. Sham, TS: * p = 0.041 vs. Sham) and hippocampus (Aβ: * p = 0.032 vs. Sham,
TS: * p = 0.038 vs. Sham). A greater increase in numbers of SPs was observed in 7-month-
old long-term denervated mice, both in cortex (Aβ: p < 0.01 vs. Sham, TS: * p = 0.026 vs.
Sham) and hippocampus (Aβ: * p = 0.044 vs. Sham, TS: * p = 0.042 vs. Sham), suggesting
that increased burden is due to an increase on the number of newly deposited SPs. Thus, our
data indicate that cholinergic lesions can rapidly increase Aβ deposition in denervated areas,
cortex and hippocampus, but also maintain a long-term synergistic effect on Aβ deposition.
Effect of Cholinergic Lesions on tau Phosphorylation
We analyzed the effect of cholinergic denervation with mu p75-SAP in tau phosphorylation
in the cortex of Wt and transgenic mice and observed an increase in tau phosphorylation in
Wt denervated mice as a consequence of administering the immunotoxin mu p75-SAP (Fig.
6). However, these values were significantly lower than those observed in transgenic mice,
suggesting that the effect might be related to the increase in Aβ deposition and not just to the
administration of the toxin. One-way ANOVA followed by Tukey-b or Tamhane tests
showed a ~4-fold increase on tau phosphorylation in all age groups of denervated transgenic
mice, including 3 months acute mice [F(3,28)=16.455, * p < 0.01 vs. other groups] (Fig. 6A),
7 months acute mice [F(3,19)=8.896, * p = 0.01 vs. other groups, † p = 0.001 vs. Wt Sham]
(Fig. 6B) and 7 months long-term mice [F(3,28)=6.720, * p=0.001 vs. other groups, †
p=0.001 vs. Wt Sham] (Fig. 6C).
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DISCUSSION
Amyloid deposition, abnormal tau phosphorylation and neurofibrillary tangle formation and
neuronal loss are the major hallmarks of AD but current animal models do not recapitulate
all of these neuropathological features. In particular, the selective early loss of cholinergic
neurons has not been modelled in the context of AD pathology. Although loss of BFB
cholinergic neurons may not be the initial neurodegenerative event in AD (7), these neurons
seem to be particularly vulnerable in AD. Presynaptic cholinergic markers are dramatically
reduced and there is marked neuronal loss in the nucleus basalis of Meynert of AD patients
(6, 27, 28). It has been previously suggested that the dual implication of choline as a
precursor for both acetylcholine and membrane phosphatidylcholine might be responsible
for this special vulnerability of cholinergic neurons (6, 29). On the other hand, Aβ, in
different states of aggregation, continues to be the main target in the development of new
therapeutic approaches although the ultimate neurotoxic mechanisms implied in the onset of
the disease are not completely understood. To establish a direct relationship between both
AD hallmarks, we hypothesized that BFB cholinergic denervation may induce or accelerate
Aβ deposition.
APP/PS1 mice show early Aβ deposition, i.e. by the age of 4 months. As in other AD
transgenic mice, however, no neuronal loss is spontaneously is observed in these animals
(11). Administering mu p75-SAP to APP/PS1 mice allows the study of a more complex
version of the illness, including specific cholinergic denervation. With this paradigm, we
observed cholinergic denervation within 7 days of injecting the toxin that reached ~40% to
50% of AChE activity in the cortex and hippocampus, without affecting non-innervated
areas, such as the striatum. We confirmed that mu p75-SAP selectively targets cholinergic
neurons bearing the receptor p75NTR without affecting parvalbumin-positive neurons (7,
14). Moreover, our behavioral data show no locomotor activity alterations in immunotoxin-
treated animals, thereby supporting the likelihood that other distant neurons, such as
Purkinje cells bearing the p75NTR receptor, are preserved. We cannot rule out the possibility
that p75NTR-positive progenitor cells in the subventricular zone or dentate gyrus (30, 31)
could be affected after the lesions; therefore, cell proliferation and neurogenesis could be
altered. However, such effects would not be expected to cause the dramatic effects on
memory and Aβ deposition that we observed.
The NOD behavioral test showed that APP/PS1 mice have episodic memory deficits as early
as 3 months of age, supporting the sensitivity of this test. This parallels observations in AD
patients who show early alterations of episodic memory (32). At older stages, we observed
that both APP/PS1 and Wt mice have decreased abilities in the NOD test and that this effect
was worsened in the presence of cholinergic lesions. Our observations were confirmed in the
Morris Water Maze test for working and spatial memory, i.e. young lesioned APP/PS1 mice
were only mildly impaired in the acquisition phase, whereas older APP/PS1 lesioned mice
showed significantly worse patterns vs. Wt or Sham-lesioned transgenic mice. Moreover,
this effect was worsened in long-term lesioned mice, i.e. those bearing a higher amyloid
burden. We observed a synergistic effect to worsen learning and memory abilities in animals
both with a cholinergic lesion and bearing the APP/PS1 transgenes, implying that
cholinergic neuron loss exacerbates age-related Aβ-induced memory deficits.
We assessed amyloid deposition in vivo using MPM. This approach allowed us to follow the
appearance of new SPs over time by re-imaging the same cortical areas for up to 3.5 months
after the cholinergic lesions. In our hands, specific BFB denervation accelerated SP
deposition in APP/PS1 mice. Previous studies have shown that 7-month-old APP/PS1 mice
deposit SPs at a similar rate to that measured here (4, 8, 26). Although at slower rates than
adults, young (~3 months old) APP/PS1 mice deposit more SPs after removing cholinergic
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innervation to the cortex than Sham operated mice. This indicates that it is not the actual
physical lesion that leads to amyloid deposition but the specific cholinergic denervation.
Similarly, adult APP/PS1 mice (~7 months of age) treated with mu p75-SAP showed higher
amyloid burden as soon as 1 week after the lesion. Moreover, although high variability was
observed, our results showed a tendency of long-term lesioned mice to maintain increased
deposition rates during the 3 months following the lesion, suggesting that the effect of
cholinergic denervation on Aβ deposition is long-lasting once the lesion is completely
established.
Although extremely powerful, our MPM does not allow us to assess other relevant brain
regions such as the hippocampus. Nevertheless, our in vivo observations that removal of
cholinergic innervation can induce and accelerate SP deposition were confirmed by
postmortem Aβ immunohistochemistry both in the cortex and hippocampus. We observed
that plaque size was not affected, implying that SPs are quite stable once deposited, as
previously described (4, 33). In fact, increased SP burden was due to a rise in SP number.
Previous studies in AD mice have shown that more nonspecific lesioning of the perforant
cortical pathways reduces APP-immunoreactivity and Aβ burden in denervated dentate
gyrus (34, 35), whereas other studies also show no effect on APP or SP deposition in the
hippocampus after fimbria-fornix transection (36). On the other hand, in other animal
modes, more specific BFB cholinergic lesions have shown some capacity to increase APP
levels in the cortex and hippocampus (37, 38), as well as increasing Aβ deposition as
amyloid angiopathy (39). In our hands, selective and specific cholinergic denervation leads
to increased SP deposition, and this effect seems to be more prominent in the cortex.
Although we were not able to detect neurofibrillary tangles using immunohistochemistry,
Western blot analysis revealed tau phosphorylation in the cortex of APP/PS1 mice, as
previously described (40); this was increased in denervated APP/PS1 mice. This finding also
underscores the relevance of our animal model as a paradigm for AD.
The underlying explanation for the selective vulnerability of different brain regions in AD
remains unclear. Previous studies in the locus coeruleus suggest that specific groups of
neurons under situations of stress may increase amyloid generation and favor Aβ
oligomerization (41). Moreover, when locus coeruleus cortical noradrenergic innervation is
removed in AD mice, augmented amyloid plaque deposits and behavioral impairments are
observed (42). A similar situation may occur in the cholinergic system. In our model,
cholinergic innervation is removed to relevant areas in learning and memory that are
specifically affected in AD. We are aware of previous studies in which increased synaptic
transmission results in increased Aβ production (43); however, reduced synaptic activity
also causes detrimental effects on synapses and memory, despite reducing plaques (44). We
cannot exclude the possibility that remaining cholinergic neurons from the BFB, or even
intracortical cholinergic neurons, might to some extent compensate for the insult, resulting
in an overall increase in synaptic transmission. Although it has been reported that precuneus
ChAT activity is reduced only when AD is completely established (45), other recent studies
have shown that cholinergic degeneration and dysfunction in AD begin before the onset of
dementia, in parallel with SP deposition (46). In this sense, treatment with muscarinic
receptor 1 agonists can reduce Aβ in AD patients, suggesting this approach as a potential
amyloid lowering therapy of AD (47, 48). Although to our knowledge the direct implication
of the cholinergic system in Aβ release or seeding has not been clarified, it has been shown
that Aβ released at the synapse may serve as seed for SP deposition. Seeds seem to migrate
along defined neuronal pathways to non-contiguous but axonally interconnected regions (49,
50). Altogether, our data suggest that cholinergic denervation may contribute to the
deposition of Aβ and synergistically contribute to learning and memory impairment, as
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observed in AD. This could also open the door to treatments that may target specific regions
(51), and that could ultimately provide a simpler therapeutic approach.
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Figure 1.
Cholinergic denervation after murine p75NTR saporin (Sap) lesions of the basal forebrain in
wild type (WT) and APP/PS1 mice. There is reduction of choline acetyltransferase
immunostaining (red) in the medial septum at 2 weeks after the lesion compared to vehicle-
treated (Sham) mice; γ-aminobutyric acid–releasing (GABAergic) neurons indicated by
parvalbumin immunostaining (green) appear preserved. Scale bar = 250 µm.
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Figure 2.
Effect of basal forebrain cholinergic denervation (Saporin) in APP/PS1 mice on episodic
memory evaluated with the new object discrimination (NOD) test. There was an overall
worsening performance with age for all paradigms under study (age X transgene effect:
what: [F(2,1)=12.243, ** p < 0.01), where: [F(2,1)=13.81, * p = 0.023), when: [F(2,1)=19.710,
** p < 0.01). There was significant impairment in 3-month-old (short term) lesioned mice
for "what", "where" and "when" parameters (* p < 0.05 vs. Wt [WT] Sham [vehicle-treated]
and WT Saporin). There was a worsening effect of cholinergic denervation in older APP/
PS1 lesioned mice (7 months old) (* p < 0.05 vs. the other groups). One-way ANOVA for
independent samples followed by Tukey-b or Tamahane test as needed.
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Figure 3.
Effect of cholinergic denervation (Saporin) in APP/PS1 mice on spatial learning and
memory evaluated using the Morris water maze test. Data are representative of 7 to 14 mice.
(A) Young mice (3 months old) had some impairment locating the hidden platform during
the 4 days of the acquisition phase; this effect was worsened in older transgenic mice (7
months), with acute and long-term cholinergic lesions. Differences were detected by two-
way ANOVA (group X day) * p < 00.5. y-axis = time to locate the hidden platform. Daily
analysis showed an overall delay to locate the platform for 3-month-old transgenic lesioned
mice (day 1: [F(3,144)=9.79, ** p < 0.01 vs. wild-type (WT) Sham], day 2: [F(3,140)=17.910,
** p < 0.01 vs. WT Sham and WT p-75 SAP, †† p < 0.01 vs. WT Sham], day 3:
[F(3,133)=17.346, ** p < 0.01 vs. other groups, †† p < 0.01 vs. WT Sham ], day 4:
[F(3,134)=14.025, ** p < 0.01 vs. other groups]). In 7-month-old mice we observed cognitive
alterations in animals bearing the APP/PS1 transgenes and we observed a worsening effect
on those animals with acute cholinergic denervation (day 1: [F(3,272)=10.611, ** p < 0.01 vs.
WT Sham], day 2: [F(3,272)=22.398, ** p < 0.01 vs. WT Sham], day 3: [F(3,262)=13.605, **
p < 0.01 vs. WT Sham and APP/PS1 Sham, †† p<0.01 vs. WT Sham], day 4:
[F(3,266)=24.109, ** p < 0.01 vs. WT Sham and APP/PS1 Sham, †† p < 0.01 vs. WT
Sham]). A similar profile was observed in 7-month-old mice with chronic cholinergic
lesions. The presence of the APP/PS1 transgenes was enough to impair learning and
memory abilities in the water maze, however this effect was worsened in the presence of the
cholinergic lesion (day 1: [F(3,141)=19.203, ** p < 0.01 vs. WT Sham], day 2:
[F(3,151)=9.385, ** p < 0.01 vs. other groups, †† vs. WT Sham], day 3: [F(3,143)=19.199 ** p
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< 0.01 vs. other groups, †† p < 0.01 vs. WT Sham], day 4: [F(3,143)=19.199, ** p < 0.01 vs.
other groups, †† p < 0.01 vs. WT Sham]). (B) During the retention phase there was
significant memory impairment in 7-month-old transgenic lesioned mice with acute and
long-term cholinergic lesions. Differences were detected using one-way ANOVA followed
by Tukey-b test.
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Figure 4.
Increased numbers of new senile plaques (SPs) in the cortex of APP/PS1 mice with and
without murine p75NTR saporin (mu p75-SAP) lesions were detected using in vivo
multiphoton microscopy. Medians, maximums and minimums are shown and statistical
differences were detected between both groups using Mann-Whitney U test for independent
samples. (A) Numbers of plaques appearing per mm3 in ~3-month-old APPswe/PS1dE9
mice 7 and 14 days after the lesions (7 days: ** p = 0.006 vs. Sham; 14 days: ** p < 0.01 vs.
Sham). When animals were compared between the day of the lesion and 120 days later there
was an increase in SPs in lesioned animals, although differences did not reach statistical
significance (p = 0.190 vs. Sham mice). (B) The same profile was observed in ~7-month-old
mice (7 days: ** p < 0.01 vs. Sham; 14 days: * p = 0.044 vs. Sham). (D–K) Examples of SP
deposition in an APPswe/PS1dE9 mouse 7 days after mu p75-SAP lesion (D, day 0; E, day
7) vs. a Sham mouse (F, day 0; G, day 7). Higher deposition was observed in lesioned
APPswe/PS1dE9 mice 120 days after surgery (H, day 0; I, day 120), vs. a Sham mouse (J,
day 0; K, day 120). The same fields were located using Texas Red dextran 70K (blue) for
the angiograms and amyloid deposits were stained with methoxy-XO4 (red). White arrows
indicate new amyloid deposits. Scale bar = 85 µm.
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Figure 5.
Postmortem assessment of senile plaque (SP) deposition with anti-β-amyloid (Aβ) antibody
and thioflavin S (TS) staining in cortex and hippocampus of APP/PS1 mice with or without
murine p75NTR saporin (mu p75-SAP)-induced lesions. (A, B) There was a significant
increase in plaque burden in all lesioned mice, although this effect was greater in 7-month-
old mice, particularly in those with long-term lesions. The increase in amyloid burden, both
in cortex (A) and hippocampus (B) was not due to increased plaque size but to an increase in
the number of new deposited SPs. Data are representative of 3 to 6 mice per group.
Statistical differences were detected by Student t-test for independent samples and Mann-
Whitney U-test for independent samples in the case of number of plaques per mm2. * p <
0.05. (C–H) Examples of Aβ immunostaining in the cortex: C, Sham 3 months acute; D, Mu
p75-SAP, 3 months acute; E, Sham 7 months acute; F, Mu p75-SAP, 7 months acute; G,
Sham 7 months long-term; H, Mu p75-SAP 7 months long-term. Scale bar = 250 µm.
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Figure 6.
Increased tau phosphorylation in transgenic mice acutely lesioned with murine p75NTR
saporin (SAP) at 3 months and 7 months of age and in long-term lesioned 7-month-old mice.
Phosphorylated tau/ total tau ratios (left panels) are expressed as percentage of wild-type
(WT) vehicle-treated (Sham) values. Differences were detected by one-way ANOVA
followed by Tukey-b test or Tamhane test as required (* p < 0.05). (A) In 3-month acute
lesions, F(3,28) = 16.455, (* p < 0.01 vs. other groups, † p = 0.001 vs. WT Sham). (B) 7-
month acute lesions F(3,19) = 8.896, (* p = 0.01 vs. other groups). (C) 7-month long-term
lesions, F(3,28) = 6.720, (* p = 0.001 vs. other groups). Right panels: Examples of western
blot for total tau, phospho-tau and α-tubulin, including APP/PS1 mu p75-SAP, APP/PS1
Sham, WT SAP and WT Sham mice.
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